The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Adrian Rawcliffe net worth and biography

Adrian Rawcliffe Biography and Net Worth

CEO of Adaptimmune Therapeutics

Adrian Rawcliffe serves as Chief Executive Officer, Director of the Company. He leads our financial strategy, management and operations functions including compliance and risk management. He has 17 years of experience within the pharmaceutical industry and most recently served as Senior Vice President, Finance of GSK's North American Pharmaceuticals business. Mr. Rawcliffe joined GSK in 1998 and his other senior roles at the company included Senior Vice President Worldwide Business Development and R&D Finance, where he was responsible for all business development and finance activities for GSK's Pharmaceuticals R&D business and Managing Partner and President of SR One Ltd, GSK's venture-capital business. Mr. Rawcliffe qualified as a chartered accountant with PricewaterhouseCoopers and holds a B.Sc. degree in Natural Sciences from the University of Durham, UK.

What is Adrian Rawcliffe's net worth?: The estimated net worth of Adrian Rawcliffe is at least $9,374.93 as of January 16th, 2024. Mr. Rawcliffe owns 14,104 shares of Adaptimmune Therapeutics stock worth more than $9,375 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Rawcliffe may own. Additionally, Mr. Rawcliffe receives an annual salary of $1,060,000.00 as CEO at Adaptimmune Therapeutics. Learn More about Adrian Rawcliffe's net worth.
How old is Adrian Rawcliffe?: Mr. Rawcliffe is currently 52 years old. There are 5 older executives and no younger executives at Adaptimmune Therapeutics. Learn More on Adrian Rawcliffe's age.
What is Adrian Rawcliffe's salary?: As the CEO of Adaptimmune Therapeutics plc, Mr. Rawcliffe earns $1,060,000.00 per year. Learn More on Adrian Rawcliffe's salary.
How do I contact Adrian Rawcliffe?: The corporate mailing address for Mr. Rawcliffe and other Adaptimmune Therapeutics executives is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. Adaptimmune Therapeutics can also be reached via phone at 441235430000 and via email at [email protected]. Learn More on Adrian Rawcliffe's contact information.
Has Adrian Rawcliffe been buying or selling shares of Adaptimmune Therapeutics?: Adrian Rawcliffe has not been actively trading shares of Adaptimmune Therapeutics during the past quarter. Most recently, Adrian Rawcliffe sold 9,304 shares of the business's stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $0.79, for a transaction totalling $7,350.16. Following the completion of the sale, the chief executive officer now directly owns 14,104 shares of the company's stock, valued at $11,142.16. Learn More on Adrian Rawcliffe's trading history.
Who are Adaptimmune Therapeutics' active insiders?: Adaptimmune Therapeutics' insider roster includes Willaim Bertrand, Jr. (COO), John Lunger (Insider), Elliot Norry (Insider), and Adrian Rawcliffe (CEO). Learn More on Adaptimmune Therapeutics' active insiders.
Are insiders buying or selling shares of Adaptimmune Therapeutics?: During the last year, insiders at the biotechnology company sold shares 7 times. They sold a total of 61,977 shares worth more than $53,507.07. The most recent insider tranaction occured on June, 18th when insider Cintia Piccina sold 24,531 shares worth more than $22,813.83. Insiders at Adaptimmune Therapeutics own 12.4% of the company. Learn More about insider trades at Adaptimmune Therapeutics.
Information on this page was last updated on 6/18/2024.

Adrian Rawcliffe Insider Trading History at Adaptimmune Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/16/2024	Sell	9,304	$0.79	$7,350.16	14,104
1/11/2024	Sell	11,945	$0.84	$10,033.80	18,395
9/1/2023	Sell	2,403	$0.78	$1,874.34	3,449
6/27/2023	Sell	2,333	$0.92	$2,146.36	3,519
1/17/2023	Sell	10,057	$1.86	$18,706.02	13,351
1/12/2023	Sell	18,763	$1.71	$32,084.73	24,882
1/4/2023	Sell	5,073	$1.69	$8,573.37	6,631
9/1/2022	Sell	2,536	$1.97	$4,995.92	3,316
6/27/2022	Sell	2,562	$1.63	$4,176.06	3,290
1/18/2022	Sell	11,096	$3.19	$35,396.24
1/11/2022	Sell	14,362	$3.56	$51,128.72
1/4/2022	Sell	5,532	$4.06	$22,459.92
9/1/2021	Sell	2,782	$5.20	$14,466.40
6/28/2021	Sell	2,794	$4.37	$12,209.78
1/19/2021	Sell	9,879	$5.67	$56,013.93
1/12/2021	Sell	2,707	$6.15	$16,648.05
1/4/2021	Sell	4,967	$5.33	$26,474.11
9/1/2020	Sell	2,776	$8.51	$23,623.76
8/3/2020	Sell	2,788	$9.25	$25,789.00
1/14/2020	Sell	3,236	$5.13	$16,600.68
1/6/2020	Sell	5,900	$1.20	$7,080.00
1/14/2019	Sell	3,084	$5.37	$16,561.08
3/20/2018	Sell	600,000	$1.71	$1,026,000.00

Adrian Rawcliffe Buying and Selling Activity at Adaptimmune Therapeutics

Adaptimmune Therapeutics Company Overview

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Today's Range

Now: $0.66

$0.64

$0.71

50 Day Range

MA: $0.85

$0.59

$1.11

2 Week Range

Now: $0.66

$0.42

$2.05

Volume

4,158,925 shs

Average Volume

1,733,154 shs

Market Capitalization

$170.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.26

Financial Prophecy

From Porter & Company | Ad

Including the name of the #1 company to buy.

Adrian Rawcliffe Biography and Net Worth

What is Adrian Rawcliffe's net worth?

How old is Adrian Rawcliffe?

What is Adrian Rawcliffe's salary?

How do I contact Adrian Rawcliffe?

Has Adrian Rawcliffe been buying or selling shares of Adaptimmune Therapeutics?

Who are Adaptimmune Therapeutics' active insiders?

Are insiders buying or selling shares of Adaptimmune Therapeutics?